Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet Good, Peyrouze P, Geffroy S, Quentin S, Alberdi An effective, Abdelali RB, Renneville Good, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-count study known the new prognostic ;31(3):555-564.
Mohamed Am, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri Meters, Tigaud I, Hayette S, Dumontet C, Cros Elizabeth, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet Yards, Ceraulo Good, Mortreux F, xmatch free trial Wattel Elizabeth. Leuk Res. 2017;-twenty eight.
Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud Yards, Perilla-Glen An effective, Aljawai Y, Huynh D, Roccaro Have always been, Sacco A great, Capelletti M, Detappe A beneficial, Alignani D, Anderson KC, Munshi NC, Do well F, Lohr JG, Ha Grams, Freeman SS, Van Allen EM, Adalsteinsson Virtual assistant, Michor F, San Miguel JF, Ghobrial I will be. 2017;19(1):218-224.
Minnema MC, Kimby Elizabeth, DSa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis Elizabeth, Kremer S, Fitsiori An excellent, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Ce Garff-Tavernier Yards, Costopoulos Meters, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Tip on the prognosis, therapy and you can response requirements to possess Yahoo-Neel problem. Haematologica. 2017;102(1):43-51.
Micol JB, Pastore An effective, Inoue D, Duployez Letter, Kim Elizabeth, Lee Sc, Durham BH, Chung Year, Cho H, Zhang XJ, Yoshimi A beneficial, Krivtsov An effective, Koche R, Solary Age, Sinha A good, Preudhomme C, Abdel-Wahab O. ASXL2 is essential having haematopoiesis and you will will act as a haploinsufficient tumour suppressor in the leukemia. Nat Commun. 2017;8:15429.
Cell Associate
Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet Meters, Wang Y, Faure P, Szymanski Grams, Duployez Letter, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Playground S. Activated clean air varieties profile handle NF-kappaB activation by lowest dosage deferasirox into the erythroid progenitors regarding reduced chance myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
Manier S, Salem KZ, Playground J, Landau Weil, Getz G, Ghobrial I am. Genomic difficulty of multiple myeloma and its own logical ramifications. Nat Rev Clin Oncol. 2017;14(2):100-113.
Manier S, Efforts JT, Sacco An effective, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta Yards, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro In the morning, Daley GQ, Ghobrial I am. The latest LIN28B/let-7 axis was a novel therapeutic pathway in the numerous myeloma. Leukemia. 2017;31(4):853-860.
Manier S, Liu CJ, Avet-Loiseau H, Playground J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A good, Roccaro Was, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller Age, Trippa L, Ghobrial Im. Prognostic character off circulating exosomal miRNAs in the numerous myeloma. Bloodstream. 2017;129(17):2429-2436.
TET2 exon 2 missing are an independent good prognostic factor to possess cytogenetically regular serious myelogenous leukemia (AML): TET2 exon dos skipping for the AML
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Playground J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brownish Ce, Gray N, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial I will be. Inhibiting the new oncogenic translation program is an effective therapeutic means within the several myeloma. Sci Transl Med. 2017;9(389).
Magnez Roentgen, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 joining education using microscale thermophoresis. Sci Associate. 2017;7(1):17623.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A beneficial, Dumezy F, Feuillard J, Genevieve F, Guerin E, Boy J, Jouault H, Lepelley P, Maynadie Yards, Solly F, Ballon OW, Preudhomme C, Baruchel A beneficial, Dombret H, Ifrah Letter, Bene MC. Prognostic value of multicenter disperse cytometry matched up investigations out of restricted recurring situation in serious myeloblastic leukemia. Hematol Oncol. 2017.